The role of cyclin D1 expression and patient's survival in non-small-cell lung cancer: A systematic review with meta-analysis

Clinical Lung Cancer

Volumn 13, Issue 3, 2012, Pages 188-195

  Zhang, Lou Qian ^a   Jiang, Feng ^a   Xu, Lin ^a   Wang, Jun ^b   Bai, Jian Ling ^a   Yin, Rong ^a   Wu, Ya Qin ^a   Meng, Li Juan ^b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Jiangsu Official Hospital   (China)

Author keywords

Cyclin D1; Lung carcinoma; Meta analysis; Overall survival; Prognosis

Indexed keywords

CYCLIN D1;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; ETHNICITY; HUMAN; LUNG NON SMALL CELL CANCER; PROTEIN EXPRESSION; SYSTEMATIC REVIEW;

CARCINOMA, NON-SMALL-CELL LUNG; CYCLIN D; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; OBSERVER VARIATION; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84859864460     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.10.003     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66. (Pubitemid 46148091)
2. Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008; 83:584-94. (Pubitemid 351720831)
3. Stamatakos M, Palla V, Karaiskos I, et al. Cell cyclins: triggering elements of cancer or not? World J Surg Oncol 2010; 8:111.
4. Besson A, Dowdy SF, Roberts JM. CDK inhibitors: cell cycle regulators and beyond. Dev Cell 2008; 14:159-69. (Pubitemid 351189186)
5. Kim JK, Diehl JA. Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol 2009; 220:292-6.
6. Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8:16.
7. Steels E, Paesmans M, Berghmans T, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 2001; 18:705-19. (Pubitemid 33040631)
8. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21:1539-58. (Pubitemid 34746062)
9. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22:719-48.
10. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-88. (Pubitemid 17189972)
11. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-34. (Pubitemid 27387172)
12. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002; 21:1559-73. (Pubitemid 34746063)
13. Zhu J, Yu L, Zhan P, et al. The relationships between cyclin D1 expression and prognosis of non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2010; 13:803-8.
14. Sterlacci W, Fiegl M, Hilbe W, et al. Deregulation of p27 and cyclin D1/D3 control over mitosis is associated with unfavorable prognosis in non-small cell lung cancer, as determined in 405 operated patients. J Thorac Oncol 2010; 5:1325-36.
15. Grossi F, Spizzo R, Bordo D, et al. Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014). J Thorac Oncol 2010; 5:1354-60.
16. Khoury T, Alrawi S, Ramnath N, et al. Eukaryotic initiation factor-4E and cyclin D1 expression associated with patient survival in lung cancer. Clin Lung Cancer 2009; 10:58-66.
17. Dworakowska D, Jassem E, Jassem J, et al. Prognostic value of the apoptotic index analysed jointly with selected cell cycle regulators and proliferation markers in nonsmall cell lung cancer. Lung Cancer 2009; 66:127-33.
18. Sanchez-Mora N, Presmanes MC, Monroy V, et al. Micropapillary lung adenocarcinoma: a distinctive histologic subtype with prognostic significance. Case series. Hum Pathol 2008; 39:324-30. (Pubitemid 351186688)
19. Li R, An SJ, Chen ZH, et al. Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients. Hum Pathol 2008; 39:1792-801.
20. Gupta VK, Feber A, Xi L, et al. Association between CCND1 G/A870 polymorphism, allele-specific amplification, cyclin D1 expression, and survival in esophageal and lung carcinoma. Clin Cancer Res 2008; 14:7804-12.
21. Esposito V, Baldi A, De Luca A, et al. Cell cycle related proteins as prognostic parameters in radically resected non-small cell lung cancer. J Clin Pathol 2005; 58:734-9. (Pubitemid 40956829)
22. Dworakowska D, Jassem E, Jassem J, et al. Prognostic value of cyclin D1 overexpression in correlation with pRb and p53 status in non-small cell lung cancer (NSCLC). J Cancer Res Clin Oncol 2005; 131:479-85. (Pubitemid 40905026)
23. Yuan JQ, Xu JY, Zhang J, et al. Expression and significance of cyclin D1, p27kip1 protein in bronchioloalveolar carcinoma. J Zhejiang Univ Sci 2004; 5:235-41.
24. Shah L, Walter KL, Borczuk AC, et al. Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma. Cancer 2004; 101:1632-8. (Pubitemid 39318911)
25. Au NH, Cheang M, Huntsman DG, et al. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J Pathol 2004; 204:101-9. (Pubitemid 39214487)
26. Ratschiller D, Heighway J, Gugger M, et al. Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival. J Clin Oncol 2003; 21:2085-93. (Pubitemid 46606356)
27. Liang RY, Liao ZS, Jiang SP, et al. Expression of cyclin D1 and vascular endothelial growth factor(VEGF) in non-small cell lung carcinoma and their association with the prognosis [in Chinese with English abstract]. Ai Zheng 2003; 22:86-90.
28. Jin M, Inoue S, Umemura T, et al. Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer 2001; 34:207-18. (Pubitemid 33010796)
29. Dosaka-Akita H, Hommura F, Mishina T, et al. A risk-stratification model of non-small cell lung cancers using cyclin E, Ki-67, and ras p21: different roles of G1 cyclins in cell proliferation and prognosis. Cancer Res 2001; 61:2500-4. (Pubitemid 32691131)
30. Nguyen VN, Mirejovsky P, Mirejovsky T, et al. Expression of cyclin D1, Ki-67 and PCNA in non-small cell lung cancer: prognostic significance and comparison with p53 and bcl-2. Acta Histochem 2000; 102:323-8.
31. Anton RC, Coffey DM, Gondo MM, et al. The expression of cyclins D1 and E in predicting short-term survival in squamous cell carcinoma of the lung. Mod Pathol 2000; 13:1167-72.
32. Mishina T, Dosaka-Akita H, Kinoshita I, et al. Cyclin D1 expression in non-smallcell lung cancers: its association with altered p53 expression, cell proliferation and clinical outcome. Br J Cancer 1999; 80:1289-95. (Pubitemid 29264094)
33. Keum JS, Kong G, Yang SC, et al. Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer. Br J Cancer 1999; 81:127-32. (Pubitemid 29415502)
34. Kawabuchi B, Moriyama S, Hironaka M, et al. p16 inactivation in small-sized lung adenocarcinoma: its association with poor prognosis. Int J Cancer 1999; 84:49-53. (Pubitemid 29059108)
35. Nishio M, Koshikawa T, Yatabe Y, et al. Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers. Clin Cancer Res 1997; 3:1051-8. (Pubitemid 27319750)
36. Caputi M, De Luca L, Papaccio G, et al. Prognostic role of cyclin D1 in non small cell lung cancer: an immunohistochemical analysis. Eur J Histochem 1997; 41:133-8. (Pubitemid 27340986)
37. Nakamura H, Kawasaki N, Taguchi M, et al. Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a meta-analysis. Cancer 2005; 103:1865-73. (Pubitemid 40563259)
38. Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005; 92:131-9. (Pubitemid 40188446)
39. Martin B, Paesmans M, Mascaux C, et al. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer 2004; 91:2018-25. (Pubitemid 40128768)
40. Martin B, Paesmans M, Berghmans T, et al. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2003; 89:55-64. (Pubitemid 36897935)
41. Zhan P, Wang J, Lv XJ, et al. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol 2009; 4:1094-103.
42. Liu L, Shao X, Gao W, et al. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J Thorac Oncol 2010; 5:1922-32.
43. Tong J, Sun X, Cheng H, et al. Expression of p16 in non-small cell lung cancer and its prognostic significance: a meta-analysis of published literatures. Lung Cancer 2011; 74:155-63.
44. Wang L, Shao ZM. Cyclin e expression and prognosis in breast cancer patients: a meta-analysis of published studies. Cancer Invest 2006; 24:581-7. (Pubitemid 44422921)